NRG1合并:街区的新孩子
Brinda Gupta1, Leila Borghaei2, Stephen V Liu3
1Lombardi Comprehensive Cancer Center, Georgetown University, 3800 Reservoir Road NW, Washington, DC, 20007, USA.
Current oncology reports
|January 31, 2025
概括
神经调节素1 (NRG1) 融合驱动非小细胞肺癌 (NSCLC) 的癌症生长. 向疗法,比如齐诺库图祖马布,为NRG1融合阳性NSCLC提供有效的治疗,新的药物正在开发中.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 遗传学 是一个遗传学.
背景情况:
- 神经调节素1 (NRG1) 融合是各种癌症的罕见致癌驱动因素,尤其是非小细胞肺癌 (NSCLC).
- 这些融合激活了HER的信号通路,促进了瘤的进展,入侵和转移.
- 具有NRG1融合阳性的NSCLC对免疫疗法和化疗等常规疗法反应不佳.
研究的目的:
- 审查NRG1融合的生物学和检测方法.
- 探索NRG1融合的NSCLC的治疗场景.
- 总结目前和新兴的NRG1融合驱动NSCLC的治疗策略.
主要方法:
- 对NSCLC中NRG1融合研究的文献综述.
- 分析当前的治疗策略和正在进行的临床试验.
- 对识别NRG1融合的诊断方法的总结.
主要成果:
- 热诺库图祖马布是一种针对HER2和HER3的双特异性抗体,是FDA批准的第一个用于先前治疗NRG1融合阳性NSCLC的治疗方法.
- NRG1融合是罕见的,但可采取行动的驱动因素,可以通过向治疗来治疗.
- 目前正在研究多种新型NRG1融合导向疗法.
结论:
- NRG1融合代表了NSCLC的一个可向子集.
- 包括泽诺库图祖马布在内的向疗法在NRG1融合阳性NSCLC中显示出有效性.
- 目前正在进行的研究正在扩大这种患者群体的治疗选择.
相关概念视频
Transducer Mechanism: Nuclear Receptors
1.3K
Nuclear receptors, or NRs, are unique transcription factors that regulate gene transcription and affect the cellular pathways involved in reproduction, development, or metabolism. Their ability to be stimulated by small lipophilic ligands and control vital cellular processes makes them ideal drug targets. Nearly 10-15% of currently prescribed drugs target these receptors.
About 48 different soluble family members of nuclear receptors are identified that can be divided into two main classes:
About 48 different soluble family members of nuclear receptors are identified that can be divided into two main classes:
1.3K
Abnormal Proliferation
4.4K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.4K
NF-κB-dependent Signaling Pathway
7.2K
The transcription factor NF-κB was discovered in 1986 in the lab of Nobel laureate Professor David Baltimore, for its interaction with the immunoglobulin light chain enhancer in B-cells. After more than three decades of study, it is now evident that NF-κB regulates the expression of over 100 genes. Most of these genes play an essential role in the innate and adaptive immune responses as well as the inflammatory responses of animals.
NF-κB-dependent Signaling Mechanism
The...
NF-κB-dependent Signaling Mechanism
The...
7.2K
Rous Sarcoma Virus (RSV) and Cancer
4.9K
Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
4.9K


